These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17436085)

  • 41. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
    Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amelioration of steatohepatitis with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet.
    Yalniz M; Bahçecioğlu IH; Kuzu N; Celebi S; Ataseven H; Ustündağ B; Ozercan IH; Sahin K
    Dig Dis Sci; 2007 Sep; 52(9):2380-6. PubMed ID: 17415655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers?
    Adams LA; Angulo P
    Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1059-60. PubMed ID: 15625648
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.
    Sharabi Y; Oron-Herman M; Kamari Y; Avni I; Peleg E; Shabtay Z; Grossman E; Shamiss A
    Am J Hypertens; 2007 Feb; 20(2):206-10. PubMed ID: 17261469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of rosiglitazone on liver structure and function in genetically diabetic Akita mice.
    Hemmeryckx B; Gaekens M; Gallacher DJ; Lu HR; Lijnen HR
    Basic Clin Pharmacol Toxicol; 2013 Nov; 113(5):353-60. PubMed ID: 23789962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
    Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
    Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator.
    Yu J; Ip E; Dela Peña A; Hou JY; Sesha J; Pera N; Hall P; Kirsch R; Leclercq I; Farrell GC
    Hepatology; 2006 Apr; 43(4):826-36. PubMed ID: 16557554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thioredoxin-binding protein-2 deficiency enhances methionine-choline deficient diet-induced hepatic steatosis but inhibits steatohepatitis in mice.
    Ahsan MK; Okuyama H; Hoshino Y; Oka S; Masutani H; Yodoi J; Nakamura H
    Antioxid Redox Signal; 2009 Oct; 11(10):2573-84. PubMed ID: 19764881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.
    Abdin AA; Baalash AA; Hamooda HE
    J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
    Aithal GP; Thomas JA; Kaye PV; Lawson A; Ryder SD; Spendlove I; Austin AS; Freeman JG; Morgan L; Webber J
    Gastroenterology; 2008 Oct; 135(4):1176-84. PubMed ID: 18718471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model.
    Costa ML; Lima-Júnior RC; Aragão KS; Medeiros RP; Marques-Neto RD; de Sá Grassi L; Leite LL; Nunes LG; de Mesquita Neto JW; de Castro Brito GA; de Souza MH; de Almeida PR; Ribeiro RA
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):711-20. PubMed ID: 25082518
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
    Torres DM; Jones FJ; Shaw JC; Williams CD; Ward JA; Harrison SA
    Hepatology; 2011 Nov; 54(5):1631-9. PubMed ID: 21748770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.
    Tzeng TF; Tzeng YC; Cheng YJ; Liou SS; Liu IM
    Nutrients; 2015 Oct; 7(10):8670-84. PubMed ID: 26506376
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Nonalcoholic steatohepatitis].
    Ratziu V; Tahiri M; Bonyhay L
    Ann Endocrinol (Paris); 2005 Apr; 66(2 Pt 2):1S71-80. PubMed ID: 15959406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.
    Zaitone SA; Barakat BM; Bilasy SE; Fawzy MS; Abdelaziz EZ; Farag NE
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Jun; 388(6):587-600. PubMed ID: 25708949
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model.
    Sahai A; Malladi P; Melin-Aldana H; Green RM; Whitington PF
    Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G264-73. PubMed ID: 15044174
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet.
    Baumgardner JN; Shankar K; Hennings L; Badger TM; Ronis MJ
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G27-38. PubMed ID: 17947452
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [PPAR gamma ligand pioglitazone as a therapeutic strategy in nonalcoholic steatohepatitis (NASH)].
    Yoneda M; Fujita K; Nakajima A; Wada K
    Nihon Yakurigaku Zasshi; 2006 Oct; 128(4):235-8. PubMed ID: 17038787
    [No Abstract]   [Full Text] [Related]  

  • 59. Rosiglitazone attenuates the severity of sodium taurocholate-induced acute pancreatitis and pancreatitis-associated lung injury.
    Chen C; Xu S; Wang WX; Ding YM; Yu KH; Wang B; Chen XY
    Arch Med Res; 2009 Feb; 40(2):79-88. PubMed ID: 19237016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rosiglitazone protects rat liver against acute liver injury associated with the NF-κB signaling pathway.
    Chen W; Lin YJ; Zhou XY; Chen H; Jin Y
    Can J Physiol Pharmacol; 2016 Jan; 94(1):28-34. PubMed ID: 26394869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.